DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,730
+1,190 (7.19%)
Jun 9, 2026, 3:30 PM KST
Market Cap799.81B +14.9%
Revenue (ttm)954.16B +13.7%
Net Income74.52B +28.5%
EPS1,659.93 +28.0%
Shares Out 45.11M
PE Ratio10.68
Forward PE8.39
Dividend200.00 (1.21%)
Ex-Dividend DateDec 29, 2025
Volume684,262
Open16,700
Previous Close16,540
Day's Range16,700 - 18,310
52-Week Range16,260 - 31,250
Beta-0.01
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements